John Greene Purchases 7,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) Director John Greene acquired 7,000 shares of the firm's stock in a transaction dated Wednesday, February 26th. The stock was bought at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the acquisition, the director now owns 7,000 shares of the company's stock, valued at approximately $313,950. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP traded down $1.63 during midday trading on Monday, hitting $42.29. The company had a trading volume of 1,721,678 shares, compared to its average volume of 2,332,421. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $84.17. The company has a market cap of $3.63 billion, a price-to-earnings ratio of -9.68 and a beta of 1.67. The company has a fifty day moving average of $42.49 and a two-hundred day moving average of $45.93.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analyst Weigh In

CRSP has been the topic of several analyst reports. Evercore ISI upgraded CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price objective for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Royal Bank of Canada reduced their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 12th. Chardan Capital reduced their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a report on Thursday, February 13th. Finally, Morgan Stanley boosted their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $74.40.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after acquiring an additional 1,474,439 shares in the last quarter. Capital International Investors raised its stake in shares of CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after acquiring an additional 816,789 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of CRISPR Therapeutics by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after acquiring an additional 1,074,238 shares in the last quarter. State Street Corp raised its stake in CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after buying an additional 599,304 shares in the last quarter. Finally, FMR LLC raised its stake in CRISPR Therapeutics by 1.0% in the third quarter. FMR LLC now owns 2,376,166 shares of the company's stock worth $111,632,000 after buying an additional 23,075 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.